Skip to main content

Peer Review reports

From: Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Original Submission
27 Jul 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
16 Sep 2022 Reviewed Reviewer Report
13 Nov 2022 Reviewed Reviewer Report
14 Jan 2023 Author responded Author comments - Sadahisa Ogasawara
Resubmission - Version 4
14 Jan 2023 Submitted Manuscript version 4
18 Jan 2023 Author responded Author comments - Sadahisa Ogasawara
Resubmission - Version 5
18 Jan 2023 Submitted Manuscript version 5
4 Feb 2023 Reviewed Reviewer Report
13 Feb 2023 Reviewed Reviewer Report
27 Feb 2023 Author responded Author comments - Sadahisa Ogasawara
Resubmission - Version 6
27 Feb 2023 Submitted Manuscript version 6
6 Mar 2023 Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
17 Mar 2023 Editorially accepted
31 Mar 2023 Article published 10.1186/s12876-023-02731-5

You can find further information about peer review here.

Back to article page